{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:29:04Z","timestamp":1794209344707,"version":"4.8.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005941","name":"Dietmar Hopp Stiftung","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005941","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Merck Serono Germany","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"German Federal Ministry of Education and Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"German Federal Ministry of Education and Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"German Federal Ministry of Education and Research","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"name":"German Federal Ministry of Education and Research","award":["01GM1908A"],"award-info":[{"award-number":["01GM1908A"]}]},{"name":"ERA-net","award":["LE3064\/2-1"],"award-info":[{"award-number":["LE3064\/2-1"]}]},{"name":"Jubilaeumsfonds of the Austrian National Bank","award":["14158 and 15918"],"award-info":[{"award-number":["14158 and 15918"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>New-generation, cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>To describe systematically the CSF profile in children with MOG-EM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Material and methods<\/jats:title>\n<jats:p>Cytological and biochemical findings (including white cell counts [WCC] and differentiation; frequency and patterns of oligoclonal bands; IgG\/IgM\/IgA and albumin concentrations and CSF\/serum ratios; intrathecal IgG\/IgM\/IgA fractions; locally produced IgG\/IgM\/IgA concentrations; immunoglobulin class patterns; IgG\/IgA\/IgM reibergrams; Link index; measles\/rubella\/zoster [MRZ] reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF <jats:sc>l<\/jats:sc>-lactate) from 108 lumbar punctures in 80 pediatric patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in 89% of samples (<jats:italic>N<\/jats:italic> = 96), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (<jats:italic>N<\/jats:italic> = 29). If present at all, intrathecal IgG synthesis was low, often transient and mostly restricted to acute attacks. Intrathecal IgM synthesis was present in 21% and exclusively detectable during acute attacks. CSF WCC were elevated in 54% of samples (median 40 cells\/\u03bcl; range 6\u2013256; mostly lymphocytes and monocytes; &gt;\u2009100\/\u03bcl in 11%). Neutrophils were present in 71% of samples; eosinophils, activated lymphocytes, and plasma cells were seen only rarely (all &lt;\u20097%). Blood\u2013CSF barrier dysfunction (as indicated by an elevated albumin CSF\/serum ratio) was present in 46% of all samples (<jats:italic>N<\/jats:italic> = 79) and at least once in 48% of all patients (<jats:italic>N<\/jats:italic> = 67) tested. CSF alterations were significantly more frequent and\/or more pronounced in patients with acute spinal cord or brain disease than in patients with acute ON and varied strongly depending on attack severity. CSF <jats:sc>l<\/jats:sc>-lactate levels correlated significantly with the spinal cord lesions load (measured in vertebral segments) in patients with acute myelitis (<jats:italic>p<\/jats:italic> = 0.0099). An analysis of pooled data from the pediatric and the adult cohort showed a significant relationship of QAlb (<jats:italic>p<\/jats:italic> &lt; 0.0005), CST TP (<jats:italic>p<\/jats:italic> &lt; 0.0001), and CSF <jats:sc>l<\/jats:sc>-lactate (<jats:italic>p<\/jats:italic> &lt; 0.0003) during acute attacks with age.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>MOG-IgG-associated EM in children is characterized by CSF features that are distinct from those in MS. With regard to most parameters, no marked differences between the pediatric cohort and the adult cohort analyzed in Part 1 were noted. Our findings are important for the differential diagnosis of pediatric MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12974-020-01825-1","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T16:04:09Z","timestamp":1599149049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients"],"prefix":"10.1186","volume":"17","author":[{"given":"Sven","family":"Jarius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Breu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Karenfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela Della","family":"Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Merkenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Thiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Blaschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Salandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Leiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pschibul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hackenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Syrbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgis","family":"Strautmanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00e4usler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Eisenk\u00f6lbl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Stoffels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eckenweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Ayzenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"H\u00f6ftberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Kleiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Korporal-Kuhnke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ringelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Schanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Reindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Wildemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Rost\u00e1sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"in cooperation with the BIOMARKER study group and the Neuromyelitis optica Study Group (NEMOS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"1825_CR1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","volume":"8","author":"S Mader","year":"2011","unstructured":"Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.","journal-title":"J Neuroinflammation"},{"key":"1825_CR2","doi-asserted-by":"crossref","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279.","DOI":"10.1186\/s12974-016-0717-1"},{"key":"1825_CR3","doi-asserted-by":"crossref","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.","DOI":"10.1186\/s12974-016-0718-0"},{"key":"1825_CR4","doi-asserted-by":"crossref","unstructured":"Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016;13:281.","DOI":"10.1186\/s12974-016-0719-z"},{"key":"1825_CR5","doi-asserted-by":"crossref","unstructured":"Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282.","DOI":"10.1186\/s12974-016-0720-6"},{"key":"1825_CR6","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00415-016-8147-7","volume":"263","author":"M Sepulveda","year":"2016","unstructured":"Sepulveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol. 2016;263:1349\u201360.","journal-title":"J Neurol"},{"key":"1825_CR7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71:276\u201383.","journal-title":"JAMA Neurol"},{"key":"1825_CR8","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, de Haidar Jorge FM, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474\u201381.","journal-title":"Neurology"},{"key":"1825_CR9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","volume":"79","author":"J Kitley","year":"2012","unstructured":"Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012;79:1273\u20137.","journal-title":"Neurology"},{"key":"1825_CR10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15:307\u201324.","journal-title":"Autoimmun Rev"},{"key":"1825_CR11","doi-asserted-by":"crossref","unstructured":"Reindl M, Jarius S, Rostasy K, Berger T: Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they? Curr Opin Neurol 2017.","DOI":"10.1097\/WCO.0000000000000446"},{"key":"1825_CR12","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1177\/1352458516631038","volume":"22","author":"M Baumann","year":"2016","unstructured":"Baumann M, Hennes EM, Schanda K, Karenfort M, Kornek B, Seidl R, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler. 2016;22:1821\u20139.","journal-title":"Mult Scler"},{"key":"1825_CR13","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","volume":"89","author":"EM Hennes","year":"2017","unstructured":"Hennes EM, Baumann M, Schanda K, Anlar B, Bajer-Kornek B, Blaschek A, et al. Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology. 2017;89:900\u20138.","journal-title":"Neurology"},{"key":"1825_CR14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","volume":"87","author":"C Lechner","year":"2016","unstructured":"Lechner C, Baumann M, Hennes EM, Schanda K, Marquard K, Karenfort M, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry. 2016;87:897\u2013905.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1825_CR15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15:89\u2013102.","journal-title":"Nat Rev Neurol"},{"key":"1825_CR16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u201389.","journal-title":"Neurology"},{"key":"1825_CR17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","volume":"9","author":"S Jarius","year":"2012","unstructured":"Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.","journal-title":"J Neuroinflammation"},{"key":"1825_CR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","volume":"176","author":"S Jarius","year":"2014","unstructured":"Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149\u201364.","journal-title":"Clin Exp Immunol"},{"key":"1825_CR19","doi-asserted-by":"crossref","unstructured":"Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8.","DOI":"10.1186\/1742-2094-10-8"},{"key":"1825_CR20","doi-asserted-by":"crossref","unstructured":"Jarius S, Wildemann B. The history of neuromyelitis optica. Part 2: \u2018Spinal amaurosis\u2019, or how it all began. J Neuroinflammation. 2019;16:280.","DOI":"10.1186\/s12974-019-1594-1"},{"key":"1825_CR21","doi-asserted-by":"crossref","first-page":"116396","DOI":"10.1016\/j.jns.2019.07.014","volume":"407","author":"S Jarius","year":"2019","unstructured":"Jarius S, Wildemann B. Devic's index case: a critical reappraisal - AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis? J Neurol Sci. 2019;407:116396.","journal-title":"J Neurol Sci"},{"key":"1825_CR22","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000062","volume":"2","author":"SS Zamvil","year":"2015","unstructured":"Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2:e62.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1825_CR23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(15)00313-0","volume":"15","author":"R Hohlfeld","year":"2016","unstructured":"Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol. 2016;15:317\u201331.","journal-title":"Lancet Neurol"},{"key":"1825_CR24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","volume":"77","author":"AK Probstel","year":"2011","unstructured":"Probstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology. 2011;77:580\u20138.","journal-title":"Neurology"},{"key":"1825_CR25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","volume":"21","author":"IA Ketelslegers","year":"2015","unstructured":"Ketelslegers IA, Van Pelt DE, Bryde S, Neuteboom RF, Catsman-Berrevoets CE, Hamann D, et al. Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort. Mult Scler. 2015;21:1513\u201320.","journal-title":"Mult Scler"},{"key":"1825_CR26","doi-asserted-by":"publisher","unstructured":"Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, H\u00fcmmert MW, Ringelstein M, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation. 2020. https:\/\/doi.org\/10.1186\/s12974-020-01824-2.","DOI":"10.1186\/s12974-020-01824-2"},{"key":"1825_CR27","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15:134.","journal-title":"J Neuroinflammation"},{"key":"1825_CR28","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485\u20139.","journal-title":"Neurology"},{"key":"1825_CR29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"BG Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006;59:566\u20139.","journal-title":"Ann Neurol"},{"key":"1825_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica study group (NEMOS). J Neurol. 2014;261:1\u201316.","journal-title":"J Neurol"},{"key":"1825_CR31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","volume":"21","author":"R Hoftberger","year":"2015","unstructured":"Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Calvo AC, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler. 2015;21:866\u201374.","journal-title":"Mult Scler"},{"key":"1825_CR32","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000257","volume":"3","author":"M Spadaro","year":"2016","unstructured":"Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e257.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1825_CR33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","volume":"84","author":"M Spadaro","year":"2018","unstructured":"Spadaro M, Winklmeier S, Beltran E, Macrini C, Hoftberger R, Schuh E, et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann Neurol. 2018;84:315\u201328.","journal-title":"Ann Neurol"},{"key":"1825_CR34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12974-018-1108-6","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, et al. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflammation. 2018;15:88.","journal-title":"J Neuroinflammation"},{"key":"1825_CR35","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","volume":"57","author":"M Andersson","year":"1994","unstructured":"Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897\u2013902.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1825_CR36","first-page":"99","volume":"4","author":"H Reiber","year":"1998","unstructured":"Reiber H. Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4:99\u2013107.","journal-title":"Mult Scler"},{"key":"1825_CR37","doi-asserted-by":"crossref","unstructured":"Reiber H. Flow rate of cerebrospinal fluid (CSF\u2014a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci. 1994;122:189\u2013203.","DOI":"10.1016\/0022-510X(94)90298-4"},{"key":"1825_CR38","volume-title":"CSF diagnostics. Guidelines and catalogue of methods of the German Society for Cerebrospinal Fluid Diagnostics and Clinical Neurochemistry","author":"HF Petereit","year":"2007","unstructured":"Petereit HF, Sindern E, Wick M. CSF diagnostics. Guidelines and catalogue of methods of the German Society for Cerebrospinal Fluid Diagnostics and Clinical Neurochemistry. Heidelberg: Springer; 2007."},{"key":"1825_CR39","doi-asserted-by":"crossref","unstructured":"Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, Ghezzi A, Hintzen R, Kornberg A, Pohl D, et al: International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19:1261\u20137.","DOI":"10.1177\/1352458513484547"},{"key":"1825_CR40","volume-title":"Multiple sclerosis and cerebrospinal fluid","author":"U Zettl","year":"2005","unstructured":"Zettl U, Tumani H. Multiple sclerosis and cerebrospinal fluid. Oxford, Malden, Victoria: Blackwell Publishing; 2005."},{"key":"1825_CR41","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1373\/clinchem.2011.177741","volume":"58","author":"DA Colantonio","year":"2012","unstructured":"Colantonio DA, Kyriakopoulou L, Chan MK, Daly CH, Brinc D, Venner AA, et al. Closing the gaps in pediatric laboratory reference intervals: a CALIPER database of 40 biochemical markers in a healthy and multiethnic population of children. Clin Chem. 2012;58:854\u201368.","journal-title":"Clin Chem"},{"key":"1825_CR42","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0009-8981(75)90257-0","volume":"65","author":"BJ Zegers","year":"1975","unstructured":"Zegers BJ, Stoop JW, Reerink-Brongers EE, Sander PC, Aalberse RC, Ballieux RE. Serum immunoglobulins in healthy children and adults. Levels of the five classes, expressed in international units per millilitre. Clin Chim Acta. 1975;65:319\u201329.","journal-title":"Clin Chim Acta"},{"key":"1825_CR43","volume-title":"Laboratory diagnosis in neurology","author":"B Wildemann","year":"2011","unstructured":"Wildemann B, Oschmann P, Reiber H. Laboratory diagnosis in neurology. Stuttgart, New York: Thieme; 2011."},{"key":"1825_CR44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00415-016-8360-4","volume":"264","author":"S Jarius","year":"2017","unstructured":"Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264:453\u201366.","journal-title":"J Neurol"},{"key":"1825_CR45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/135245859800400304","volume":"4","author":"H Reiber","year":"1998","unstructured":"Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998;4:111\u20137.","journal-title":"Mult Scler"},{"key":"1825_CR46","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/jnnp.2007.133330","volume":"79","author":"S Jarius","year":"2008","unstructured":"Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP, Petereit HF, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2008;79:1134\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1825_CR47","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ejpn.2017.03.006","volume":"21","author":"V Kahlmann","year":"2017","unstructured":"Kahlmann V, Roodbol J, van Leeuwen N, Ramakers CRB, van Pelt D, Neuteboom RF, et al. Validated age-specific reference values for CSF total protein levels in children. Eur J Paediatr Neurol. 2017;21:654\u201360.","journal-title":"Eur J Paediatr Neurol"},{"key":"1825_CR48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1743-8454-2-3","volume":"2","author":"HF Petereit","year":"2005","unstructured":"Petereit HF, Reske D. Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications. Cerebrospinal Fluid Res. 2005;2:3.","journal-title":"Cerebrospinal Fluid Res"},{"key":"1825_CR49","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/1352458509348418","volume":"15","author":"H Reiber","year":"2009","unstructured":"Reiber H, Teut M, Pohl D, Rostasy KM, Hanefeld F. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult Scler. 2009;15:1466\u201380.","journal-title":"Mult Scler"},{"key":"1825_CR50","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/archneur.64.12.1802-a","volume":"64","author":"D Franciotta","year":"2007","unstructured":"Franciotta D, Jarius S, Aloisi F. More on multiple sclerosis and neuromyelitis optica. Arch Neurol. 2007;64:1802 author reply 1802-1803.","journal-title":"Arch Neurol"},{"key":"1825_CR51","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archneur.64.6.899","volume":"64","author":"BG Weinshenker","year":"2007","unstructured":"Weinshenker BG. Neuromyelitis optica is distinct from multiple sclerosis. Arch Neurol. 2007;64:899\u2013901.","journal-title":"Arch Neurol"},{"key":"1825_CR52","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1001\/archneur.64.6.901","volume":"64","author":"SL Galetta","year":"2007","unstructured":"Galetta SL, Bennett J. Neuromyelitis optica is a variant of multiple sclerosis. Arch Neurol. 2007;64:901\u20133.","journal-title":"Arch Neurol"},{"key":"1825_CR53","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/archneur.64.6.906","volume":"64","author":"ES Roach","year":"2007","unstructured":"Roach ES. Is neuromyelitis optica a distinct entity? Arch Neurol. 2007;64:906.","journal-title":"Arch Neurol"},{"key":"1825_CR54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1084\/jem.163.1.41","volume":"163","author":"MJ Walsh","year":"1986","unstructured":"Walsh MJ, Tourtellotte WW. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med. 1986;163:41\u201353.","journal-title":"J Exp Med"},{"key":"1825_CR55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306:82\u201390.","journal-title":"J Neurol Sci"},{"key":"1825_CR56","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/archneurol.2010.269","volume":"67","author":"SR Kalluri","year":"2010","unstructured":"Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, Bennett JL, et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol. 2010;67:1201\u20138.","journal-title":"Arch Neurol"},{"key":"1825_CR57","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","volume":"7","author":"S Jarius","year":"2010","unstructured":"Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7:52.","journal-title":"J Neuroinflammation"},{"key":"1825_CR58","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/1352458511403958","volume":"17","author":"S Jarius","year":"2011","unstructured":"Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler. 2011;17:1067\u201373.","journal-title":"Mult Scler"},{"key":"1825_CR59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","volume":"18","author":"DM Wingerchuk","year":"2012","unstructured":"Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler. 2012;18:5\u201310.","journal-title":"Mult Scler"},{"key":"1825_CR60","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/art.27337","volume":"62","author":"KP Wandinger","year":"2010","unstructured":"Wandinger KP, Stangel M, Witte T, Venables P, Charles P, Jarius S, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum. 2010;62:1198\u2013200.","journal-title":"Arthritis Rheum"},{"key":"1825_CR61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0002-9343(99)80135-1","volume":"99","author":"SG West","year":"1995","unstructured":"West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med. 1995;99:153\u201363.","journal-title":"Am J Med"},{"key":"1825_CR62","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.md.0000141099.53742.16","volume":"83","author":"S Delalande","year":"2004","unstructured":"Delalande S, de Seze J, Fauchais AL, Hachulla E, Stojkovic T, Ferriby D, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83:280\u201391.","journal-title":"Medicine (Baltimore)"},{"key":"1825_CR63","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53:1107\u201314.","journal-title":"Neurology"},{"key":"1825_CR64","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jns.2008.08.002","volume":"280","author":"S Jarius","year":"2009","unstructured":"Jarius S, Eichhorn P, Jacobi C, Wildemann B, Wick M, Voltz R. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J Neurol Sci. 2009;280:98\u2013100.","journal-title":"J Neurol Sci"},{"key":"1825_CR65","first-page":"486","volume":"253","author":"S Jarius","year":"2006","unstructured":"Jarius S, Franciotta D, Marchioni E, Hohlfeld R, Wildemann B, Voltz R. Intrathecal polyspecific immune response against neurotropic viruses discriminates between multiple sclerosis and acute demyelinating encephalomyelitis. J Neurol. 2006;253:486.","journal-title":"J Neurol"},{"key":"1825_CR66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1212\/01.WNL.0000070782.27949.F7","volume":"61","author":"K Rostasy","year":"2003","unstructured":"Rostasy K, Reiber H, Pohl D, Lange P, Ohlenbusch A, Eiffert H, et al. Chlamydia pneumoniae in children with MS: frequency and quantity of intrathecal antibodies. Neurology. 2003;61:125\u20138.","journal-title":"Neurology"},{"key":"1825_CR67","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1515\/CCLM.2010.127","volume":"48","author":"S Jarius","year":"2010","unstructured":"Jarius S, Franciotta D, Bergamaschi R, Wildemann B, Wandinger KP. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin Chem Lab Med. 2010;48:659\u201363.","journal-title":"Clin Chem Lab Med"},{"key":"1825_CR68","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125:1450\u201361.","journal-title":"Brain"},{"key":"1825_CR69","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008;131:3072\u201380.","journal-title":"Brain"},{"key":"1825_CR70","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/archpedi.154.8.827","volume":"154","author":"M Wong","year":"2000","unstructured":"Wong M, Schlaggar BL, Buller RS, Storch GA, Landt M. Cerebrospinal fluid protein concentration in pediatric patients: defining clinically relevant reference values. Arch Pediatr Adolesc Med. 2000;154:827\u201331.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"1825_CR71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp.63.4.446","volume":"63","author":"PJ Jongen","year":"1997","unstructured":"Jongen PJ, Lamers KJ, Doesburg WH, Lemmens WA, Hommes OR. Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;63:446\u201351.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1825_CR72","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archneur.1967.00470230044005","volume":"16","author":"JB Posner","year":"1967","unstructured":"Posner JB, Plum F. Independence of blood and cerebrospinal fluid lactate. Arch Neurol. 1967;16:492\u20136.","journal-title":"Arch Neurol"},{"key":"1825_CR73","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/s-0028-1103944","volume":"104","author":"TO Kleine","year":"1979","unstructured":"Kleine TO, Baerlocher K, Niederer V, Keller H, Reutter F, Tritschler W, et al. Diagnostic significance of lactate concentration in CSF in patients with meningitis (author's transl). Dtsch Med Wochenschr. 1979;104:553\u20137.","journal-title":"Dtsch Med Wochenschr"},{"key":"1825_CR74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ana.410020202","volume":"2","author":"RA Fishman","year":"1977","unstructured":"Fishman RA, Sligar K, Hake RB. Effects of leukocytes on brain metabolism in granulocytic brain edema. Ann Neurol. 1977;2:89\u201394.","journal-title":"Ann Neurol"},{"key":"1825_CR75","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archinte.1983.00350010089015","volume":"143","author":"GW Jordan","year":"1983","unstructured":"Jordan GW, Statland B, Halsted C. CSF lactate in diseases of the CNS. Arch Intern Med. 1983;143:85\u20137.","journal-title":"Arch Intern Med"},{"key":"1825_CR76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1600-0404.1988.tb03610.x","volume":"78","author":"HW Kolmel","year":"1988","unstructured":"Kolmel HW, von Maravic M. Correlation of lactic acid level, cell count and cytology in cerebrospinal fluid of patients with bacterial and non-bacterial meningitis. Acta Neurol Scand. 1988;78:6\u20139.","journal-title":"Acta Neurol Scand"},{"key":"1825_CR77","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/jcbfm.1989.57","volume":"9","author":"NE Andersen","year":"1989","unstructured":"Andersen NE, Gyring J, Hansen AJ, Laursen H, Siesjo BK. Brain acidosis in experimental pneumococcal meningitis. J Cereb Blood Flow Metab. 1989;9:381\u20137.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1825_CR78","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1085\/jgp.100.2.341","volume":"100","author":"L Simchowitz","year":"1992","unstructured":"Simchowitz L, Textor JA. Lactic acid secretion by human neutrophils. Evidence for an H+ + lactate- cotransport system. J Gen Physiol. 1992;100:341\u201367.","journal-title":"J Gen Physiol"},{"key":"1825_CR79","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0304-3940(88)90499-5","volume":"86","author":"W Walz","year":"1988","unstructured":"Walz W, Mukerji S. Lactate production and release in cultured astrocytes. Neurosci Lett. 1988;86:296\u2013300.","journal-title":"Neurosci Lett"},{"key":"1825_CR80","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/glia.440010603","volume":"1","author":"W Walz","year":"1988","unstructured":"Walz W, Mukerji S. Lactate release from cultured astrocytes and neurons: a comparison. Glia. 1988;1:366\u201370.","journal-title":"Glia"},{"key":"1825_CR81","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1084\/jem.20081241","volume":"205","author":"SR Hinson","year":"2008","unstructured":"Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med. 2008;205:2473\u201381.","journal-title":"J Exp Med"},{"key":"1825_CR82","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.mehy.2013.10.011","volume":"81","author":"S Jarius","year":"2013","unstructured":"Jarius S, Wildemann B. Aquaporin-4 antibodies, CNS acidosis and neuromyelitis optica: a potential link. Med Hypotheses. 2013;81:1090\u20135.","journal-title":"Med Hypotheses"},{"key":"1825_CR83","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1523\/JNEUROSCI.3780-05.2006","volume":"26","author":"E Alberdi","year":"2006","unstructured":"Alberdi E, Sanchez-Gomez MV, Torre I, Domercq M, Perez-Samartin A, Perez-Cerda F, et al. Activation of kainate receptors sensitizes oligodendrocytes to complement attack. J Neurosci. 2006;26:3220\u20138.","journal-title":"J Neurosci"},{"key":"1825_CR84","doi-asserted-by":"crossref","first-page":"175628641876208","DOI":"10.1177\/1756286418762083","volume":"11","author":"MS Weber","year":"2018","unstructured":"Weber MS, Derfuss T, Metz I, Bruck W. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord. 2018;11:1756286418762083.","journal-title":"Ther Adv Neurol Disord"},{"key":"1825_CR85","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458515622986","volume":"22","author":"S Jarius","year":"2016","unstructured":"Jarius S, Metz I, Konig FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016;22:1541\u20139.","journal-title":"Mult Scler"},{"key":"1825_CR86","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1212\/01.WNL.0000148481.80152.BF","volume":"63","author":"J Correale","year":"2004","unstructured":"Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology. 2004;63:2363\u201370.","journal-title":"Neurology"},{"key":"1825_CR87","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"key":"1825_CR88","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12974-017-1043-y","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Wurthwein C, Behrens JR, Wanner J, Haas J, Paul F, et al. Balo's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures. J Neuroinflammation. 2018;15:22.","journal-title":"J Neuroinflammation"},{"key":"1825_CR89","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12974-019-1425-4","volume":"16","author":"S Jarius","year":"2019","unstructured":"Jarius S, Haas J, Paul F, Wildemann B. Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures. J Neuroinflammation. 2019;16:51.","journal-title":"J Neuroinflammation"},{"key":"1825_CR90","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12974-017-0929-z","volume":"14","author":"S Jarius","year":"2017","unstructured":"Jarius S, Konig FB, Metz I, Ruprecht K, Paul F, Bruck W, et al. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. J Neuroinflammation. 2017;14:171.","journal-title":"J Neuroinflammation"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01825-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-020-01825-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01825-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T13:10:34Z","timestamp":1630674634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-020-01825-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1186\/s12974-020-01825-1","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local review boards of the participating centers. The patients\u2019 parents\/caregivers gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.J. was indirectly supported by research grants from the Dietmar Hopp Stiftung and from Merck Serono to the Department of Neurology, University Hospital Heidelberg, Germany (to B.W.). C.L. reports no conflicts of interest. E.W. reports no conflicts of interest. M.Ba. reports no conflicts of interest. M.Br. reports no conflicts of interest. M.S. reports no conflicts of interest. M.K. reports no conflicts of interest. A.DM. reports no conflicts of interest. A.M. reports no conflicts of interest. C.T. reports no conflicts of interest. A.B. has received travel grands and speakers honoraria from Merck Serono, Genzyme, Sanofi and has served on scientific advisory boards for Novartis. M.S. reports no conflicts of interest. S.L. reports no conflicts of interest. F.L. reports speakers honoraria from Grifols, Teva, Biogen, Bayer, Roche, Novartis, Fresenius, travel funding from Merck, Grifols, and Bayer and serving on advisory boards for Roche, Biogen and Alexion. A.P. reports no conflicts of interest. A.H. reports no conflicts of interest. C.K. reports no conflicts of interest. A.H. reports no conflicts of interest. S.S. reports no conflicts of interest. J.S. reports no conflicts of interest. M.H. reports no conflicts of interest. P.K. reports no conflicts of interest. A.E. reports no conflicts of interest. J.S. reports no conflicts of interest. M.E. reports no conflicts of interest. I.A. has received travel grants from Biogen Idec and the Guthy-Jackson Charitable Foundation, has served on scientific advisory boards for Roche and Alexion and has received research support from Chugai Pharma. J.H. reports no conflicts of interest. I.K. has received travel funding and\/or speaker honoraria from Biogen, Merck, Mylan, Novartis, Sanofi, Roche, has consulted for Alexion, Bayer, Chugai, Roche, Shire, has received research support from Chugai and Diamed, and is Associate Editor of BMC Neurology. M.K.K. reports no conflicts of interest. M.Ri. has received speaker honoraria from Novartis, Bayer Vital GmbH and Ipsen, has served on scientific advisory boards for Roche, and received travel reimbursement from Bayer Schering, Biogen Idec, Merz, Genzyme, Teva, Merck and the Guthy-Jackson Charitable Foundation, none related to this study. P.S.R. reports speaker honoraria from Abbvie, Daiichi-Sankyo, Merck, Roche, Biogen, Novartis, Shire; he reports consultancy honoraria from Roche, Merck, Teva, Sandoz\/Hexal; and research grants from Biogen, Merck, Roche; none of them resultant in a conflict of interest with regards to the submitted work. K.Ru. has received research support from Novartis, Merck Serono, and the German Federal Ministry of Education and Research; speaker honoraria and travel grants from Bayer, Biogen Idec, Merck Serono, Sanofi-Aventis\/Genzyme, Teva, Roche, Novartis, and the Guthy Jackson Charitable Foundation. N.S. has received travel funding from Sanofi-Aventis\/Genzyme. O.A. has received grants from the German Research Foundation (DFG) and the German Federal Ministry of Education and Research (BMBF) as part of the \u2018German Competence Network Multiple Sclerosis\u2019 (KKNMS; FKZ 01GI1602B); grants from Biogen, Merck Serono, Novartis, Sanofi and Teva; personal fees from Biogen, Merck Serono, Novartis, Sanofi, Roche, and Teva. F.P. has received honoraria and research support from Alexion, Bayer, Biogen, Chugai, MerckSerono, Novartis, Genzyme, MedImmune, Shire, Teva, and serves on scientific advisory boards for Alexion, MedImmune and Novartis; he has received funding from Deutsche Forschungsgemeinschaft (DFG Exc 257), the German Federal Ministry of Education and Research (Competence Network Multiple Sclerosis), the Guthy Jackson Charitable Foundation, the EU Framework Program 7, and the National Multiple Sclerosis Society of the USA. M.R. was supported by research grants from the Austrian Science Funds (FWF), Austrian Science Promotion Agency (FFG) and the Austrian Multiple Sclerosis Research Society. The University Hospital and Medical University of Innsbruck (Austria; M.R. and K.Sch.) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (L\u00fcbeck, Germany). B.W. has received research grants and\/or honoraria from Merck Serono, Biogen, Teva, Novartis, Sanofi Genzyme, and Bayer Healthcare, and research grants from the Dietmar Hopp Foundation, the Klaus Tschira Foundation, the German Federal Ministry of Education and Research (BMBF; FKZ 01GI1602A), and Deutsche Forschungsgemeinschaft (DFG). K.R. has no conflict of interest related to this project.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"262"}}